Based in Bridgewater, NJ, Savient Pharmaceuticals (NASDAQ:SVNT) is the operator of a specialty biopharmaceutical company. The company develops and markets pharmaceutical products that target unmet medical needs in niche and broader specialty markets. Savient’s global biologics business features a diverse portfolio of products including EUFLEXXA, a hyaluronic acid product for the amelioration of knee pain due to osteoarthritis, BioLon, a hyaluronic acid product for use in ophthalmic surgery, and Bio-Tropin, a human growth hormone product for the treatment of growth hormone deficient children.
The Winning Solution
The principals of Genoa Partners worked on the strategic sale of Savient’s global biologics business to Ferring because they were seeking niche marketing specialty products with manageable physician prescribing audiences and were able to lock in on the global rights to market EUFLEXXA. In addition, EUFLEXXA represents an additional specialty marketing opportunity that expands Ferring’s US product line beyond infertility. The deal also included the acquisition of the biologics business’s modern, purpose-built biotech manufacturing facility at Be’er Tuvia, Israel.
Ferring Pharmaceuticals is a Swiss-based operator of a research-driven, biopharmaceutical group dedicated to helping people around the world. The company focuses on reproductive medicine and women’s health and specializes in gastroenterology and urology medicine for women and babies. Ferring has a direct local marketing presence in more than 50 countries and distribution in 110 countries.